Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 87

1.

Low Sodium Diet Decreases Stone Formation in Genetic Hypercalciuric Stone-Forming Rats.

Krieger NS, Grynpas M, VandenEynde A, Asplin JR, Frick KK, Kim MH, Ramos FM, Granja I, Bushinsky DA.

Nephron. 2019 Feb 6:1-11. doi: 10.1159/000497117. [Epub ahead of print]

PMID:
30726853
2.

The Effect of Lemonade and Diet Lemonade Upon Urinary Parameters Affecting Calcium Urinary Stone Formation.

Cheng JW, Wagner H, Asplin JR, Hodgkin G, Schlaifer A, Fargusson M, Fargusson J, Baldwin DD.

J Endourol. 2019 Feb;33(2):160-166. doi: 10.1089/end.2018.0623.

PMID:
30585747
3.

Impact of Regular or Extended Hemodialysis and Hemodialfiltration on Plasma Oxalate Concentrations in Patients With End-Stage Renal Disease.

Ermer T, Kopp C, Asplin JR, Granja I, Perazella MA, Reichel M, Nolin TD, Eckardt KU, Aronson PS, Finkelstein FO, Knauf F.

Kidney Int Rep. 2017 Jun 8;2(6):1050-1058. doi: 10.1016/j.ekir.2017.06.002. eCollection 2017 Nov.

4.

Evidence for a role of PDZ domain-containing proteins to mediate hypophosphatemia in calcium stone formers.

Bergsland KJ, Coe FL, Parks JH, Asplin JR, Worcester EM.

Nephrol Dial Transplant. 2018 May 1;33(5):759-770. doi: 10.1093/ndt/gfx284.

PMID:
29126251
5.

Analyte variations in consecutive 24-hour urine collections in children.

Ellison JS, Hollingsworth JM, Langman CB, Asplin JR, Schwaderer AL, Yan P, Bierlein M, Barraza MA, Defoor WR, Figueroa TE, Jackson EC, Jayanthi VR, Johnson EK, Joseph DB, Shnorhavorian M.

J Pediatr Urol. 2017 Dec;13(6):632.e1-632.e7. doi: 10.1016/j.jpurol.2017.06.014. Epub 2017 Jul 12.

PMID:
28739373
6.

Steatorrhea and Hyperoxaluria in Severely Obese Patients Before and After Roux-en-Y Gastric Bypass.

Moreland AM, Santa Ana CA, Asplin JR, Kuhn JA, Holmes RP, Cole JA, Odstrcil EA, Van Dinter TG Jr, Martinez JG, Fordtran JS.

Gastroenterology. 2017 Apr;152(5):1055-1067.e3. doi: 10.1053/j.gastro.2017.01.004. Epub 2017 Jan 12.

PMID:
28089681
7.

The role of the 24-h urine collection in the management of nephrolithiasis.

Ennis JL, Asplin JR.

Int J Surg. 2016 Dec;36(Pt D):633-637. doi: 10.1016/j.ijsu.2016.11.020. Epub 2016 Nov 11. Review.

8.

Molecular modifiers reveal a mechanism of pathological crystal growth inhibition.

Chung J, Granja I, Taylor MG, Mpourmpakis G, Asplin JR, Rimer JD.

Nature. 2016 Aug 25;536(7617):446-50. Epub 2016 Aug 17.

PMID:
27501150
9.

Loss of Cystic Fibrosis Transmembrane Regulator Impairs Intestinal Oxalate Secretion.

Knauf F, Thomson RB, Heneghan JF, Jiang Z, Adebamiro A, Thomson CL, Barone C, Asplin JR, Egan ME, Alper SL, Aronson PS.

J Am Soc Nephrol. 2017 Jan;28(1):242-249. doi: 10.1681/ASN.2016030279. Epub 2016 Jun 16.

10.

How Much Information is Lost When You Only Collect One 24-Hour Urine Sample during the Initial Metabolic Evaluation?

Alruwaily AF, Dauw CA, Bierlein MJ, Yan P, Asplin JR, Ghani KR, Wolf JS Jr, Hollingsworth JM.

J Urol. 2016 Oct;196(4):1143-8. doi: 10.1016/j.juro.2016.04.074. Epub 2016 Apr 29.

PMID:
27140069
11.

The management of patients with enteric hyperoxaluria.

Asplin JR.

Urolithiasis. 2016 Feb;44(1):33-43. doi: 10.1007/s00240-015-0846-5. Epub 2015 Dec 8. Review.

PMID:
26645872
12.

Geographic Variation in the Quality of Secondary Prevention for Nephrolithiasis.

Alruwaily AF, Dauw CA, Bierlein MJ, Asplin JR, Ghani KR, Wolf JS Jr, Hollingsworth JM.

Urology. 2015 Sep;86(3):454-8. doi: 10.1016/j.urology.2015.05.022. Epub 2015 Jun 11.

PMID:
26210006
13.

Prospective evaluation of urinary metabolic indices in severely obese adolescents after weight loss surgery.

DeFoor WR, Asplin JR, Kollar L, Jackson E, Jenkins T, Schulte M, Inge T.

Surg Obes Relat Dis. 2016 Feb;12(2):363-7. doi: 10.1016/j.soard.2015.03.013. Epub 2015 Mar 28.

14.

Effect of Potassium Citrate on Calcium Phosphate Stones in a Model of Hypercalciuria.

Krieger NS, Asplin JR, Frick KK, Granja I, Culbertson CD, Ng A, Grynpas MD, Bushinsky DA.

J Am Soc Nephrol. 2015 Dec;26(12):3001-8. doi: 10.1681/ASN.2014121223. Epub 2015 Apr 8.

15.

The effect of a diet containing 70% protein from plants on mineral metabolism and musculoskeletal health in chronic kidney disease.

Moorthi RN, Armstrong CL, Janda K, Ponsler-Sipes K, Asplin JR, Moe SM.

Am J Nephrol. 2014;40(6):582-91. doi: 10.1159/000371498. Epub 2015 Jan 20.

16.

Provider variation in the quality of metabolic stone management.

Dauw CA, Alruwaily AF, Bierlein MJ, Asplin JR, Ghani KR, Wolf JS Jr, Hollingsworth JM.

J Urol. 2015 Mar;193(3):885-90. doi: 10.1016/j.juro.2014.09.111. Epub 2014 Oct 5.

PMID:
25286012
17.

Persistence of 1,25D-induced hypercalciuria in alendronate-treated genetic hypercalciuric stone-forming rats fed a low-calcium diet.

Frick KK, Asplin JR, Culbertson CD, Granja I, Krieger NS, Bushinsky DA.

Am J Physiol Renal Physiol. 2014 May 1;306(9):F1081-7. doi: 10.1152/ajprenal.00680.2013. Epub 2014 Feb 26.

18.

1,25(OH)ā‚‚Dā‚ƒ induces a mineralization defect and loss of bone mineral density in genetic hypercalciuric stone-forming rats.

Ng AH, Frick KK, Krieger NS, Asplin JR, Cohen-McFarlane M, Culbertson CD, Kyker-Snowman K, Grynpas MD, Bushinsky DA.

Calcif Tissue Int. 2014 May;94(5):531-43. doi: 10.1007/s00223-014-9838-7. Epub 2014 Jan 31.

19.

Specificity of growth inhibitors and their cooperative effects in calcium oxalate monohydrate crystallization.

Farmanesh S, Ramamoorthy S, Chung J, Asplin JR, Karande P, Rimer JD.

J Am Chem Soc. 2014 Jan 8;136(1):367-76. doi: 10.1021/ja410623q. Epub 2013 Dec 20.

PMID:
24313314
20.

1,25(OH)ā‚‚Dā‚ƒ-enhanced hypercalciuria in genetic hypercalciuric stone-forming rats fed a low-calcium diet.

Frick KK, Asplin JR, Krieger NS, Culbertson CD, Asplin DM, Bushinsky DA.

Am J Physiol Renal Physiol. 2013 Oct 15;305(8):F1132-8. doi: 10.1152/ajprenal.00296.2013. Epub 2013 Aug 7.

21.

Effects of Sex on Intra-Individual Variance in Urinary Solutes in Stone-Formers Collected from a Single Clinical Laboratory.

Perry GM, Scheinman SJ, Asplin JR.

PLoS One. 2013 Jun 19;8(6):e53637. doi: 10.1371/journal.pone.0053637. Print 2013.

22.

Monosodium urate stones are rare, and urine pH is not low in cystinuria.

Asplin JR, Penniston K, Goldfarb DS.

Am J Kidney Dis. 2013 Jul;62(1):179-80. doi: 10.1053/j.ajkd.2013.03.041. No abstract available.

23.

NALP3-mediated inflammation is a principal cause of progressive renal failure in oxalate nephropathy.

Knauf F, Asplin JR, Granja I, Schmidt IM, Moeckel GW, David RJ, Flavell RA, Aronson PS.

Kidney Int. 2013 Nov;84(5):895-901. doi: 10.1038/ki.2013.207. Epub 2013 Jun 5.

24.

A pilot study of the effect of sodium thiosulfate on urinary lithogenicity and associated metabolic acid load in non-stone formers and stone formers with hypercalciuria.

Okonkwo OW, Batwara R, Granja I, Asplin JR, Goldfarb DS.

PLoS One. 2013 Apr 8;8(4):e60380. doi: 10.1371/journal.pone.0060380. Print 2013.

25.

Struvite urolithiasis and chronic urinary tract infection in a murine model of urinary diversion.

Becknell B, Carpenter AR, Bolon B, Asplin JR, Ingraham SE, Hains DS, Schwaderer AL, McHugh KM.

Urology. 2013 May;81(5):943-8. doi: 10.1016/j.urology.2013.02.003. Epub 2013 Mar 20.

26.

Increased biological response to 1,25(OH)(2)D(3) in genetic hypercalciuric stone-forming rats.

Frick KK, Asplin JR, Favus MJ, Culbertson C, Krieger NS, Bushinsky DA.

Am J Physiol Renal Physiol. 2013 Mar 15;304(6):F718-26. doi: 10.1152/ajprenal.00645.2012. Epub 2013 Jan 23.

27.

The Interaction of thiol drugs and urine pH in the treatment of cystinuria.

Asplin DM, Asplin JR.

J Urol. 2013 Jun;189(6):2147-51. doi: 10.1016/j.juro.2012.12.031. Epub 2012 Dec 20.

PMID:
23261477
28.

Effect of vitamin D repletion on urinary calcium excretion among kidney stone formers.

Leaf DE, Korets R, Taylor EN, Tang J, Asplin JR, Goldfarb DS, Gupta M, Curhan GC.

Clin J Am Soc Nephrol. 2012 May;7(5):829-34. doi: 10.2215/CJN.11331111. Epub 2012 Mar 15.

29.

Urine risk factors in children with calcium kidney stones and their siblings.

Bergsland KJ, Coe FL, White MD, Erhard MJ, DeFoor WR, Mahan JD, Schwaderer AL, Asplin JR.

Kidney Int. 2012 Jun;81(11):1140-8. doi: 10.1038/ki.2012.7. Epub 2012 Feb 22.

30.

Weight, age and coefficients of variation in renal solute excretion.

Perry GM, Scheinman SJ, Asplin JR.

Nephron Physiol. 2012;122(1-2):13-8. doi: 10.1159/000346148. Epub 2013 Mar 19.

PMID:
23595094
31.

Effect of diet orange soda on urinary lithogenicity.

Sumorok NT, Asplin JR, Eisner BH, Stoller ML, Goldfarb DS.

Urol Res. 2012 Jun;40(3):237-41. doi: 10.1007/s00240-011-0418-2. Epub 2011 Aug 20.

32.

Variability in urinary oxalate measurements between six international laboratories.

Maalouf NM, Adams Huet B, Pasch A, Lieske JC, Asplin JR, Siener R, Hesse A, Nuoffer JM, Frey FJ, Knight J, Holmes RP, Zerwekh JE, Bonny O.

Nephrol Dial Transplant. 2011 Dec;26(12):3954-9. doi: 10.1093/ndt/gfr147. Epub 2011 Mar 31.

33.

Chlorthalidone improves vertebral bone quality in genetic hypercalciuric stone-forming rats.

Bushinsky DA, Willett T, Asplin JR, Culbertson C, Che SP, Grynpas M.

J Bone Miner Res. 2011 Aug;26(8):1904-12. doi: 10.1002/jbmr.374.

34.

Vegetarian compared with meat dietary protein source and phosphorus homeostasis in chronic kidney disease.

Moe SM, Zidehsarai MP, Chambers MA, Jackman LA, Radcliffe JS, Trevino LL, Donahue SE, Asplin JR.

Clin J Am Soc Nephrol. 2011 Feb;6(2):257-64. doi: 10.2215/CJN.05040610. Epub 2010 Dec 23.

35.

Evidence for net renal tubule oxalate secretion in patients with calcium kidney stones.

Bergsland KJ, Zisman AL, Asplin JR, Worcester EM, Coe FL.

Am J Physiol Renal Physiol. 2011 Feb;300(2):F311-8. doi: 10.1152/ajprenal.00411.2010. Epub 2010 Dec 1.

36.

Medicine. Stopping the stones.

Coe FL, Asplin JR.

Science. 2010 Oct 15;330(6002):325-6. doi: 10.1126/science.1197207. No abstract available.

PMID:
20947749
37.

Analysis of 24-hour urine parameters as it relates to age of onset of cystine stone formation.

Lambert EH, Asplin JR, Herrell SD, Miller NL.

J Endourol. 2010 Jul;24(7):1179-82. doi: 10.1089/end.2010.0133.

PMID:
20624086
38.

Citrate, malate and alkali content in commonly consumed diet sodas: implications for nephrolithiasis treatment.

Eisner BH, Asplin JR, Goldfarb DS, Ahmad A, Stoller ML.

J Urol. 2010 Jun;183(6):2419-23. doi: 10.1016/j.juro.2010.02.2388. Epub 2010 Apr 18.

PMID:
20403610
39.

The effect of restrictive bariatric surgery on urinary stone risk factors.

Semins MJ, Asplin JR, Steele K, Assimos DG, Lingeman JE, Donahue S, Magnuson T, Schweitzer M, Matlaga BR.

Urology. 2010 Oct;76(4):826-9. doi: 10.1016/j.urology.2010.01.037. Epub 2010 Apr 8.

PMID:
20381135
40.

Thiosulfate reduces calcium phosphate nephrolithiasis.

Asplin JR, Donahue SE, Lindeman C, Michalenka A, Strutz KL, Bushinsky DA.

J Am Soc Nephrol. 2009 Jun;20(6):1246-53. doi: 10.1681/ASN.2008070754. Epub 2009 Apr 15.

41.

Obesity and urolithiasis.

Asplin JR.

Adv Chronic Kidney Dis. 2009 Jan;16(1):11-20. doi: 10.1053/j.ackd.2008.10.003. Review.

PMID:
19095201
42.

Effect of two sports drinks on urinary lithogenicity.

Goodman JW, Asplin JR, Goldfarb DS.

Urol Res. 2009 Feb;37(1):41-6. doi: 10.1007/s00240-008-0166-0. Epub 2008 Dec 10.

PMID:
19066876
43.

Prevalence of hyperoxaluria after bariatric surgery.

Patel BN, Passman CM, Fernandez A, Asplin JR, Coe FL, Kim SC, Lingeman JE, Assimos DG.

J Urol. 2009 Jan;181(1):161-6. doi: 10.1016/j.juro.2008.09.028. Epub 2008 Nov 14.

44.

Protein content of human apatite and brushite kidney stones: significant correlation with morphologic measures.

Pramanik R, Asplin JR, Jackson ME, Williams JC Jr.

Urol Res. 2008 Oct;36(5):251-8. doi: 10.1007/s00240-008-0151-7. Epub 2008 Sep 9.

45.

Evaluation of the kidney stone patient.

Asplin JR.

Semin Nephrol. 2008 Mar;28(2):99-110. doi: 10.1016/j.semnephrol.2008.01.001. Review.

PMID:
18359391
46.

Nephrolithiasis: introduction.

Asplin JR.

Semin Nephrol. 2008 Mar;28(2):97-8. doi: 10.1016/j.semnephrol.2008.02.001. No abstract available.

PMID:
18359390
47.

Effect of bolus and divided feeding on urine ions and supersaturation in genetic hypercalciuric stone-forming rats.

Bushinsky DA, Michalenka AC, Strutz KL, Donahue S, Asplin JR.

Kidney Int. 2008 Feb;73(4):423-9. Epub 2007 Nov 28.

48.

A randomized, controlled trial of lactic acid bacteria for idiopathic hyperoxaluria.

Goldfarb DS, Modersitzki F, Asplin JR.

Clin J Am Soc Nephrol. 2007 Jul;2(4):745-9. Epub 2007 May 30.

49.

Hyperoxaluria in kidney stone formers treated with modern bariatric surgery.

Asplin JR, Coe FL.

J Urol. 2007 Feb;177(2):565-9.

PMID:
17222634
50.

Urine calcium excretion predicts bone loss in idiopathic hypercalciuria.

Asplin JR, Donahue S, Kinder J, Coe FL.

Kidney Int. 2006 Oct;70(8):1463-7. Epub 2006 Aug 30.

Supplemental Content

Loading ...
Support Center